Recombinant in vitro assembled hepatitis C virus core particles induce strong specific immunity enhanced by formulation with an oil-based adjuvant

Biological Research

Volumn 42, Issue 1, 2009, Pages 41-56

  Acosta Rivero, Nelson ^a   Poutou, Joanna ^a   Álvarez Lajonchere, Liz ^a   Guerra, Ivis ^a   Aguilera, Yaraima ^a   Musacchio, Alexis ^a   Rodríguez, Armando ^a   Aguilar, Julio C ^a   Falcon, Viviana ^a   Álvarez Obregon, Julio C ^a   Soria, Yordanka ^a   Torres, Dinorah ^a   Linares, Marbelis ^a   Pérez, Angel ^a   Morales Grillo, Juan ^a   Dueñas Carrera, Santiago ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Adjuvant; Capsid; Challenge; HCV; Immunity

Indexed keywords

ALUMINUM HYDROXIDE; GAMMA INTERFERON; HEPATITIS C ANTIBODY; HEPATITIS C ANTIGEN; HEPATITIS C CORE ANTIGEN; IMMUNOLOGICAL ADJUVANT; MONTANIDE ISA 888; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BAGG ALBINO MOUSE; CELL COUNT; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DRUG DOSE COMPARISON; DRUG FORMULATION; FEMALE; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO GENE TRANSFER; INFECTION CONTROL; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; SPLEEN CELL; TH1 CELL; VACCINIA; VIRUS CORE; VIRUS LIKE AGENT; VIRUS LOAD; VIRUS PARTICLE; VIRUS RECOMBINANT;

ANIMALIA; HEPATITIS C VIRUS; MIRIDAE; MUS; VACCINIA VIRUS;

EID: 70350004092     PISSN: 07169760     EISSN: 07176287     Source Type: Journal    
DOI: 10.4067/S0716-97602009000100005     Document Type: Article

References (55)

1. ACOSTA-RIVERO N, DUEÑAS-CARRERA S, ÁLVAREZ-LAJONCHERE L, MORALES-GRILLO J (2004) HCV core protein-expressing DNA vaccine induces a strong class I-binding peptide DTH response in mice. Biochem Biophys Res Commun 314: 781-786
2. ACOSTA-RIVERO N, POUTOU J, MUSSACHIO A, FALCON V, AGUILERA Y, RODRÍGUEZ A, PÉREZ A, AGUILAR JC, DE LA ROSA MC, ÁLVAREZ F, MORALES-GRILLO J, KOURI J and DUEÑAS-CARRERA S (2005) Interaction of a C-terminal Truncated Hepatitis C Virus Core Protein with Plasmid DNA Vaccine Leads to in vitro Assembly of Heterogeneous Virus-like Particles. Am J Infect Dis 1: 66-72
3. ACOSTA-RIVERO N, RODRÍGUEZ A, MUSSACHIO A, POUTOU J, FALCÓN V, TORRES D, AGUILAR JC, LINARES M, ALONSO M, PÉREZ A, MENÉNDEZ I, MORALES-GRILLO J, MacARQUEZ G, DUEÑAS-CARRERA S (2005b) A C-terminal truncated hepatitis C virus core protein variant assembles in vitro into virus-like particles in the absence of structured nucleic acids. Biochem Biophys Res Commun 334: 901-906
4. AGUILAR JC, ACOSTA-RIVERO N, DUEÑAS-CARRERA S, MORALES GRILLO J, PICHARDO D, URQUIZA D, GUILLEN G, MUZIO V (2003) HCV core protein modulates the immune response against the HBV surface antigen in mice. Biochem Biophys Res Commun 310: 59-63
5. ÁLVAREZ-LAJONCHERE L, DUEÑAS-CARRERA S, VINA A, RAMOS T, PICHARDO D, MORALES J (2002) Additives and Protein-DNA Combinations Modulate the Humoral Immune Response Elicited by a Hepatitis C Virus Core-encoding Plasmid in Mice. Mem Inst Oswaldo Cruz 97: 95-99
6. ÁLVAREZ-LAJONCHERE L, GONZÁLEZ M, ÁLVAREZ-OBREGON JC, GUERRA I, VIÑA A, ACOSTA-RIVERO N, MUSACCHIO A, MORALES J, DUEÑAS-CARRERA S (2006) Hepatitis C virus (HCV) core protein enhances the immunogenicity of a co-delivered DNA vaccine encoding HCV structural antigens in mice. Biotechnol Appl Biochem 44: 9-17
7. ÁLVAREZ-LAJONCHERE L, GUERRA I, AMADOR-CAÑIZARES Y, FRÍAS R, VAZQUEZ-BLOMQUIST D, MORALES J, DUEÑAS-CARRERA S (2008) Generation and characterization of recombinant vaccinia viruses expressing a hepatitis C virus Core protein, genotype 1b, individually or as a polyprotein. Biotecnologia Aplicada; 24: 246-253
8. ÁLVAREZ-OBREGON JC, DUENAS-CARRERA S, VALENZUELA C, GRILLO JM (2001) A truncated HCV core protein elicits a potent immune response with a strong participation of cellular immunity components in mice. Vaccine 19: 3940-3946
9. ANDRÉ P, KOMURIAN-PRADEL F, DEFORGES S, PERRET M, BERLAND JL, SODOYER M, POL S, BRÉCHOT C, PARANHOS-BACCALÀ G, LOTTEAU V (2002) Characterization of low- and very-lowdensity hepatitis C virus RNA-containing particles. J Virol 76: 6919-6928
10. BAHNEMANN HG, MESQUITA JA (1987) Oil adjuvant vaccine against foot and mouth disease. Bol Centr Panam Fiebre Aftosa 53: 25-30
11. BOTARELLI P, BRUNETTO MR, MINUTELLO MA, CALVO P, UNUTMAZ D, WEINER AJ, CHOO QL, SHUSTER JR, KUO G, BONINO F (1993) Tlymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 104: 580-587
12. BUKH J, PURCELL RH, MILLER RH (1994) Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci USA 91: 8239-8243
13. BUNGENER L, GEERAEDTS F, TER VEER W, MEDEMA J, WILSCHUT J, HUCKRIEDE A (2008) Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 26: 2350-2359
14. CHIBA J, OHBA H, MATSUURA Y, WATANABE Y, KATAYAMA T, KIKUCHI S, SAITO I, MIYAMURA T (1991) Serodiagnosis of hepatitis C virus (HCV) infection with an HCV core protein molecularly expressed by a recombinant baculovirus. Proc Natl Acad Sci USA 88: 4641-4645
15. CHOO QL, KUO G, WEINER AJ, OVERBY LR, BRADLEY DW, HOUGHTON M (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359-362
16. COX JC, COULTER AR (1997) Adjuvants a classification and review of their modes of action. Vaccine 15: 248-256
17. DREUX M, COSSET FL (2007) The scavenger receptor BI and its ligand, HDL: partners in crime against HCV neutralizing antibodies. J Viral Hepat 14: 68-76
18. DUEÑAS-CARRERA S, ÁLVAREZ-LAJONCHERE L, ÁLVAREZ-OBREGÓN JC, PÉREZ A, ACOSTA-RIVERO N, VÁZQUEZ DM, MARTÍNEZ G, VIÑA A, PICHARDO D, MORALES J (2002) Enhancement of the immune response generated against the hepatitis C virus envelope proteins after DNA vaccination with polyprotein-encoding plasmids. Biotechnol Appl Biochem 35: 205-212
19. GRAKOUI A, SHOUKRY NH, WOOLLARD DJ, HAN JH, HANSON HL, GHRAYEB J, MURTHY KK, RICE CM, WALKER CM (2003) HCV persistence and immune evasion in the absence of memory T cell help. Science 302: 659-662
20. GRAMENZI A, ANDREONE P, LOGGI E, FOSCHI FG, CURSARO C, MARGOTTI M, BISELLI M, BERNARDI M (2005) Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. J Viral Hepat 12: 525-530
21. HARASE I, MORIYAMA T, KANEKO T, KITA H, NOMURA M, SUZUKI G, OHNISHI H, MUTO Y, YAZAKI Y, IMAWARI M (1995) Immune response to hepatitis C virus core protein in mice. Immunol Cell Biol 73: 346-352
22. ISHIDA S, KAITO M, KOHARA M, TSUKIYAMA-KOHORA K, FUJITA N, IKOMA J, ADACHI Y, WATANABE S (2001) Hepatitis C virus core particle detected by immunoelectron microscopy and optical rotation technique. Hepatol Res 20: 335-347
23. JACKSON P, PETRIK J, ALEXANDER GJ, PEARSON G, ALLAIN JP (1997) Reactivity of synthetic peptides representing selected sections of hepatitis C virus core and envelope proteins with a panel of hepatitis C virus-seropositive human plasma. J Med Virol 51: 67-79
24. JIN H, LI Y, MA Z, ZHANG F, XIE Q, GU D, WANG B (2004) Effect of chemical adjuvants on DNA vaccination. Vaccine 22: 2925-2935
25. KAKIMI K, KURIBAYASHI K, IWASHIRO M, MASUDA T, SAKAI M, LING W, KUBO Y, KOBAYASHI H, HIGO K, SEKI M (1995) Hepatitis C virus core region: helper T cell epitopes recognized by BALB/c and C57BL/6 mice. J Gen Virol 76: 1205-1214
26. KÜNDIG TM, BACHMANN MF, OEHEN S, HOFFMANN UW, SIMARD JJ, KALBERER CP, PIRCHER H, OHASHI PS, HENGARTNER H, ZINKERNAGEL RM (1996) On the role of antigen in maintaining cytotoxic T-cell memory. Proc Natl Acad Sci USA 93: 9716-9723
27. LECHMANN M, MURATA K, SATOI J, VERGALLA J, BAUMERT TF, LIANG TJ (2001) Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology 34: 417-423
28. LECHNER F, WONG DK, DUNBAR PR, CHAPMAN R, CHUNG RT, DOHRENWEND P, ROBBINS G, PHILLIPS R, KLENERMAN P, WALKER BD (2000) Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191: 1499-1512
29. LORENZO LJ, DUEÑAS-CARRERA S, FALCÓN V, ACOSTA-RIVERO N, GONZÁLEZ E, DE LA ROSA MC, MENÉNDEZ I, MORALES J (2001) Assembly of truncated HCV core antigen into virus-like particles in Escherichia coli. Biochem Biophys Res Commun 281: 962-965
30. MAILLARD P, KRAWCZYNSKI K, NITKIEWICZ J, BRONNERT C, SIDORKIEWICZ M, GOUNON P, DUBUISSON J, FAURE G, CRAINIC R, BUDKOWSKA A (2001) Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients. J Virol 75: 8240-8250
31. MARTÍNEZ-DONATO G, CAPDESUÑER Y, ACOSTA-RIVERO N, RODRÍGUEZ A, MORALES-GRILLO J, MARTÍNEZ E, GONZÁLEZ M, ÁLVAREZ-OBREGÓN JC, DUEÑAS-CARRERA S (2007) Multimeric HCV E2 Protein Obtained From Pichia pastoris Cells Induces a Strong Immune Response in Mice. Mol Biotechnol 35: 225-236
32. MEDZHITOV R, JANEWAY CA (1997) Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 91: 4-9
33. MISSALE G, BERTONI R, LAMONACA V, VALLI A, MASSARI M, MORI C, RUMI MG, HOUGHTON M, FIACCADORI F, FERRARI C (1996) Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 98: 706-714
34. MOREAU I, LEVIS J, CROSBIE O, KENNY-WALSH E, FANNING LJ (2008) Correlation between pretreatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a. Virol J 5: 78
35. MORON VG, RUEDA P, SEDLIK C, LECLERC C (2003) In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J Immunol 171: 2242-2250
36. MURATA K, LECHMANN M, QIAO M, GUNJI T, ALTER HJ, LIANG TJ (2003) Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci USA 100: 6753-6758
37. NEUMANN-HAEFELIN C, SPANGENBERG HC, BLUM HE, THIMME R (2007) Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection. World J Gastroenterol 13: 4839-4847
38. NOVAK N, ALLAM JP, BETTEN H, HABERSTOK J, BIEBER T (2004) The role of antigen presenting cells at distinct anatomic sites: they accelerate and they slow down allergies. Allergy 59: 5-14
39. POL S, BOURLIÈRE M (2006) Optimizing treatment outcomes in chronic hepatitis C: management of nonresponse. Antivir Ther 11: 955-970
40. RIEDL P, STOBER D, OEHNINGER C, MELBER K, REIMANN J, SCHIRMBECK R (2002) Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain. J Immunol 168: 4951-4959
41. ROOHVAND F, AGHASADEGHI MR, SADAT SM, BUDKOWSKA A, KHABIRI AR (2007) HCV core protein immunization with Montanide/CpG elicits strong Th1/Th2 and long-lived CTL responses. Biochem Biophys Res Commun 354: 641-649
42. ROSEN HR, MINER C, SASAKI AW, LEWINSOHN DM, CONRAD AJ, BAKKE A, BOUWER HG, HINRICHS DJ (2002) Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology 35: 190-198
43. RUSHBROOK SM, HOARE M, ALEXANDER GJ (2007) T-regulatory lymphocytes and chronic viral hepatitis. Expert Opin Biol Ther 7: 1689-1703
44. SHIINA M, REHERMANN B (2006) Hepatitis C vaccines: Inducing and challenging memory T cells. Hepatology 43: 1395-1398
45. SHOUKRY NH, GRAKOUI A, HOUGHTON M, CHIEN DY, GHRAYEB J, REIMANN KA, WALKER CM (2003) Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 197: 1645-1655
46. SINGH M, SRIVASTAVA I (2003) Advances in vaccine adjuvants for infectious diseases. Curr HIV Res 1: 309-320
47. STORNI T, LECHNER F, ERDMANN I, BÄCHI T, JEGERLEHNER A, DUMRESE T, KÜNDIG TM, RUEDL C, BACHMANN MF (2002) Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with viruslike particles. J Immunol 168: 2880-2886
48. STORNI T, RUEDL C, RENNER WA, BACHMANN MF (2003) Innate immunity together with duration of antigen persistence regulate effector T cell induction. J Immunol 171: 795-801
49. STRADER DB, WRIGHT T, THOMAS DL, SEEFF LB, American Association for the Study of Liver Diseases (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39: 1147-1171
50. THIMME R, OLDACH D, CHANG KM, STEIGER C, RAY SC, CHISARI FV (2001) Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194: 1395-1406
51. TIMM J, ROGGENDORF M (2007) Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J Gastroenterol 13: 4808-4817
52. Winther B, Innes DJ (1994) The human adenoid. A morphologic study, Arch Otolaryngol Head Neck Surg 120: 144-149
53. YOUN JW, PARK SH, LAVILLETTE D, COSSET FL, YANG SH, LEE CG, JIN HT, KIM CM, SHATA MT, LEE DH, PFAHLER W, PRINCE AM, SUNG YC (2005) Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology 42: 1429-1436
54. ZEISEL MB, FAFI-KREMER S, FOFANA I, BARTH H, STOLL-KELLER F, DOFFOEL M, BAUMERT TF (2007) Neutralizing antibodies in hepatitis C virus infection. World J Gastroenterol 13: 4824-4830
55. ZHANG YY, GUO LS, HAO LJ, HANSSON BG, WIDELL A, NORDENFELT E (1993) Antibodies to hepatitis C virus and hepatitis C virus RNA in Chinese blood donors determined by ELISA, recombinant immunoblot assay and polymerase chain reaction. Chin Med J 106: 171-174